Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common diabetes drug fix a rare heart condition?

NCT ID NCT07146880

Disease control Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This small study will test whether empagliflozin, a drug typically used for diabetes, can improve abnormal heart patterns in people with Brugada syndrome. Ten participants will take the drug daily for three months, and researchers will monitor their heart rhythms and any side effects. The goal is to see if the drug can reduce the risk of dangerous heart events.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Empagliflozin (a diabetes drug that lowers blood sugar by helping the kidneys remove it)
What this could lead to
If it works, this could point toward a new treatment option for Brugada syndrome, a rare heart condition that can cause dangerous heart rhythms.
What could go wrong
This is a very small early-phase trial with only 10 people, so results may not apply to everyone. The drug also has known side effects like infections and kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients diagnosed with Brugada syndrome and aged 18-99 years with spontaneous type 1 ECG, normal structural heart and patent coronary artery 2. Obtain written informed consent for participation in the clinical trial Exclusion Criteria: 1. Individuals with type 1 ECG pattern only observed with fever-induced or drug-induced were excluded from this exploratory study. 2. Current or prior use of an SGLT2 inhibitor within 12 weeks before screening or randomization 3. Known allergy or hypersensitivity to any SGLT2 inhibitor 4. History of ketoacidosis 5. Symptomatic hypotension or systolic blood pressure \<90 mmHg or \>180 mmHg 6. Heart failure 7. Acute myocardial infarction 8. ALT or AST \>3× ULN at screening 9. Impaired renal function (eGFR \<20 mL/min/1.73 m² \[MDRD\]), requiring dialysis, or functioning kidney transplant at screening 10. Pregnancy, nursing, or planning pregnancy during the trial 11. Enrollment in another investigational drug or device study or completion of such a study within the last 30 days 12. Known poor adherence to clinic visits or prescribed medications 13. Medical conditions that may limit trial participation, including severe respiratory disease, history of cancer with metastasis in the past four years (excluding non-melanoma skin cancer), or recent alcohol/substance misuse

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brugada syndrome (BRS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Brugada syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brugada syndrome (BRS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Taiwan University Hospital

    Taipei, Taiwan, 100, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.